Do you want to take action against Alzheimer’s, just like me? See below the full overview of our studies.
Take action against Alzheimer’s
What we’ve achieved so far
75+
Trials
250+
Participants
3
Locations
Our Alzheimer’s trials
Filter
The goal of this study is to evaluate how safe and effective the new drug GV1001 is for the treatment of participants with mild to moderate stage Alzheimer’s Disease. The study compares the effect of the new drug GV1001 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered through a subcutaneous injection.
55 - 85 years
Mild to moderate stage Alzheimer’s disease
58 weeks
Amsterdam, Den Bosch and Zwolle
The goal of this study is to evaluate how safe and effective the new drug CT1812 is for the treatment of participants with mild to moderate Alzheimer’s disease. The study compares the effect of the new drug CT1812 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered orally.
50 - 85 years
Mild to moderate Alzheimer’s disease
Approximately 9 months
Amsterdam, Den Bosch and Zwolle
The goal of this study is to evaluate how safe and effective the new drug TW001 is for the treatment of participants with early stage Alzheimer’s disease. The study compares the effect of the new drug TW001 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug consists of granules which are dissolved in water.
55 - 80 years
Early stage Alzheimer's disease
Approximately 17 weeks
Amsterdam and Den Bosch
The goal of this study is to evaluate how safe and effective the new drug ALN-APP is for the treatment of participants with MCI or mild dementia due to early onset Alzheimer’s disease, where the disease began before the participant was 65 years old. The study compares the effect of the new drug ALN-APP with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered through an injection into the fluid surrounding the spinal cord.
18+
Alzheimer’s or mild dementia due to early onset Alzheimer’s disease
152 weeks
Amsterdam
The goal of this study is to evaluate how safe and effective the new drug REM0046127 is for the treatment of participants with mild to moderate Alzheimer’s disease. The study compares the effect of the new drug REM0046127 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered orally.
50 - 85 years
Mild to moderate Alzheimer's disease
9 weeks
Amsterdam
The goal of this study is to evaluate how safe and effective the new drug ALZ-801 is for the treatment of participants with early-stage Alzheimer’s disease and ApoE4/4 genotype. The study compares the effect of the new drug ALZ-801 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is taken in the form of a tablet.
50 - 80 years
Early-stage Alzheimer’s disease and ApoE4/4 genotype
93 weeks
Amsterdam, Den Bosch, and Zwolle
Let us know how we can help you
Do you have any questions or would you like to know more about one of our studies? Contact us by phone or email. We are happy to help you.
What do our participants say?
“The most important thing is that there is a solution.”
“With my participation, I may also help others,” says Mr. Arts, one of our participants.
